Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,616.85
(
0.08%
)
US TECH 100
24,206.80
(
2.83%
)
Dow Jones
46,584.46
(
-0.18%
)
Brent Oil
91.88
(
-9.22%
)
Bitcoin
71,700.15
(
-0.40%
)
News Focus
News Focus
Post# of 10280
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

MomsSpaghetti

Send PM Follow Ignore
Followers 85
Posts 5826
Boards Moderated 5
Alias Born 08/21/2015

MomsSpaghetti

Re: None

Monday, 11/18/2024 8:14:03 AM

Monday, November 18, 2024 8:14:03 AM

Post# of 10280
Pratt's approval of Brintellix (vortioxetine) for major depressive disorder (MDD)

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/020427Orig1s016%2C022006Orig1s018ltr.pdf

Lundbeck Pharmaceuticals: In his role as Vice President of U.S. Regulatory Affairs, Dr. Pratt contributed to the approval of therapies like Brintellix (vortioxetine) for major depressive disorder.

We already had an amazing team. We're getting MM-120 approved with them working together. This went from the Bad News Bears to a championship winning team.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent DFTX News
More DFTX News